Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Eyes Oncology Franchise With Acquisition Of Ligand Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.
Advertisement

Related Content

Epizyme Builds A Cancer Company At Mach Speed
Ligand Takes Out Neurogen For At Least $11 Million
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Japanese Biotechs Promote “Relationship Building” In Developing Marketing Deals
Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
FDA Warning Letter Targets Ligand Oncologics
Merck’s Zolinza Approved For Rare Skin Cancer
King Buys Avinza Rights From Ligand
Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients
Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients

Topics

Advertisement
UsernamePublicRestriction

Register

PS064984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel